Cutaneous adnexal carcinosarcoma: Immunohistochemical and molecular evidence of epithelial mesenchymal transition

Cutaneous carcinosarcomas are rare biphenotypic tumors that simultaneously show epithelial and mesenchymal differentiation. The most common carcinomatous components in skin carcinosarcomas are basal cell carcinoma and squamous cell carcinoma; adnexal carcinomas are rarely encountered. We report a case of an adnexal carcinoma with ductal and squamous differentiation and spindle cell component, which is interpreted as carcinosarcoma. Loss of immunohistochemical expression of E‐cadherin and β‐catenin detected in the sarcomatous component suggested epithelial mesenchymal transition (EMT). RNA sequencing analysis identified several gene mutations and alterations such as translocations and upregulations/downregulations, either shared by the two components of the tumor or differentially present in the carcinoma or the sarcoma parts. Thus, mutations in genes, such as TP53, were found in both components of the tumor while mutations in PDGFRA and RB1 (a pathogenic missense mutation) were exclusively present in the sarcomatous areas, further supporting EMT. EMT is a dynamic process by which tumors acquire mesenchymal phenotype while simultaneously losing epithelial properties. Although the pathways involved in EMT have been extensively studied, this phenomenon still needs to be investigated in cutaneous tumors of adnexal origin for a better understanding of their pathogenesis. These molecular changes may represent promising targets for personalized therapies.

[1]  M. Nakashima,et al.  Cutaneous pilomatrical carcinosarcoma: a case report with molecular analysis and literature review , 2020, Diagnostic Pathology.

[2]  Yihua Zhang,et al.  Long Non-Coding RNA Plasmacytoma Variant Translocation 1 (PVT1) Enhances Proliferation, Migration, and Epithelial-Mesenchymal Transition (EMT) of Pituitary Adenoma Cells by Activating β-Catenin, c-Myc, and Cyclin D1 Expression , 2019, Medical science monitor : international medical journal of experimental and clinical research.

[3]  S. Ong,et al.  Molecular Basis of Tumor Heterogeneity in Endometrial Carcinosarcoma , 2019, Cancers.

[4]  P. Hershberger,et al.  Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy. , 2019, Trends in cancer.

[5]  Kevin K. Chang,et al.  RETRACTED ARTICLE: Platelet-derived growth factor receptor-α and -β promote cancer stem cell phenotypes in sarcomas , 2018, Oncogenesis.

[6]  F. Afaq,et al.  Potential therapeutic targets of epithelial-mesenchymal transition in melanoma. , 2017, Cancer letters.

[7]  Feng Zhu,et al.  Long Noncoding RNA PVT1 Promotes EMT and Cell Proliferation and Migration Through Downregulating p21 in Pancreatic Cancer Cells , 2017, Technology in cancer research & treatment.

[8]  S. Florell,et al.  Cutaneous carcinosarcoma: a series of six cases and a review of the literature , 2017, Journal of cutaneous pathology.

[9]  S. Dalle,et al.  [Malignant transformation of an eccrine spiradenoma]. , 2017, Annales de dermatologie et de venereologie.

[10]  Hye-Min Jeon,et al.  MET: roles in epithelial-mesenchymal transition and cancer stemness. , 2017, Annals of translational medicine.

[11]  Haibo Hu,et al.  High expression of lncRNA PVT1 promotes invasion by inducing epithelial-to-mesenchymal transition in esophageal cancer , 2016, Oncology letters.

[12]  F. Gao,et al.  Hes1 triggers epithelial-mesenchymal transition (EMT)-like cellular marker alterations and promotes invasion and metastasis of nasopharyngeal carcinoma by activating the PTEN/AKT pathway , 2015, Oncotarget.

[13]  N. Palanisamy,et al.  Cutaneous basal cell carcinosarcomas: evidence of clonality and recurrent chromosomal losses. , 2015, Human pathology.

[14]  R. Cason,et al.  Cutaneous carcinosarcoma and the EMT: to transition, or not to transition? That is the question , 2015, Virchows Archiv.

[15]  M. Garcia-Blanco,et al.  Carcinosarcomas: tumors in transition? , 2015, Histology and histopathology.

[16]  R. Darley,et al.  Factors Affecting the Nuclear Localization of β‐Catenin in Normal and Malignant Tissue , 2014, Journal of cellular biochemistry.

[17]  R. Cason,et al.  Cutaneous carcinosarcoma: further insights into its mutational landscape through massive parallel genome sequencing , 2014, Virchows Archiv.

[18]  R. Cason,et al.  Primary cutaneous carcinosarcoma: insights into its clonal origin and mutational pattern expression analysis through next-generation sequencing. , 2013, Human pathology.

[19]  S. Al-Sarraj,et al.  Distinct Phenotypic Differences Associated with Differential Amplification of Receptor Tyrosine Kinase Genes at 4q12 in Glioblastoma , 2013, PloS one.

[20]  E. Oliva,et al.  Oncogene alterations in endometrial carcinosarcomas. , 2013, Human pathology.

[21]  Youngsuk Lee,et al.  Primary cutaneous carcinosarcoma of the shoulder: case report with literature review. , 2013, Dermatologic Surgery.

[22]  H. Meijers-Heijboer,et al.  RB1 mutations and second primary malignancies after hereditary retinoblastoma , 2011, Familial Cancer.

[23]  M. Amrani,et al.  Primary Carcinosarcoma of the Skin , 2010, Journal of Hand and Microsurgery.

[24]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[25]  J. Stevenson,et al.  Are primary cutaneous carcinisarcomas underdiagnosed? Five cases and a review of the literature. , 2006, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[26]  P. Saadat,et al.  Case report and literature review: primary cutaneous carcinosarcoma. , 2005, Annals of clinical and laboratory science.

[27]  J. Carlson,et al.  Cutaneous carcinosarcoma: adnexal vs. epidermal types define high‐ and low‐risk tumors. Results of a meta‐analysis , 2005, Journal of cutaneous pathology.

[28]  S. Glanz,et al.  β‐catenin expression in benign and malignant pilomatrix neoplasms , 2004, The British journal of dermatology.

[29]  M. Stone,et al.  Proliferating trichilemmal tumor with a malignant spindle cell component , 2002, Journal of cutaneous pathology.

[30]  W. McCluggage,et al.  Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? , 2002, Journal of clinical pathology.

[31]  N. Yamazaki,et al.  Malignant Eccrine Spiradenoma: A Case Report and Review of the Literature , 2001, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[32]  M. Tokunaga,et al.  Malignant eccrine spiradenoma with smooth muscle cell differentiation: Histological and immunohistochemical study , 1996, Pathology international.

[33]  R. Ashfaq,et al.  Carcinosarcoma arising in eccrine spiradenoma of the breast. Report of a case and review of the literature. , 1996, Archives of pathology & laboratory medicine.

[34]  M. P. Saunders,et al.  Carcinosarcoma of skin , 1995, Histopathology.

[35]  W. Allsbrook,et al.  Pilomatrical carcinosarcoma of the cheek with subsequent pulmonary metastases. A case report. , 1994, The American Journal of dermatopathology.

[36]  M. Huerre,et al.  [Carcinosarcoma arising in eccrine spiradenoma. A morphologic and immunohistochemical study]. , 1994, Annales de Pathologie.

[37]  J. Val-Bernal,et al.  Malignant aneuploid spindle-cell transformation in a proliferating trichilemmal tumour. , 1993, Acta Dermato-Venereologica.

[38]  L. Philipson,et al.  Epidural anesthesia with 0.5% bupivacaine: influence of age on sensory and motor blockade. , 1991, Anesthesia and analgesia.

[39]  C. Fletcher,et al.  Carcinosarcoma Arising in Eccrine Spiradenoma: A Clinicopathologic and Immunohistochemical Study of Two Cases , 1990, The American Journal of dermatopathology.

[40]  G. Ricevuti,et al.  The potential malignancy of eccrine spiradenoma. , 1989, The Italian journal of surgical sciences.

[41]  T. Warner Proliferating Pilar Cyst with Spindle Cell Component , 1979, Journal of cutaneous pathology.

[42]  Dawson Ek Carcino-sarcoma of the skin. , 1972 .